

FOR IMMEDIATE RELEASE

From PhenoTech, Inc.

MEDIA CONTACT: Guy Maestre, 610-761-7311

PhenoTech Moves Into Its New Research Facilities

PHILADELPHIA, February 12, 2007 -- PhenoTech, Inc. a privately held biopharmaceutical company pioneering the discovery, development and commercialization of a highly innovative class of reagents for diagnostic use in blood banks announced today that it is moving into its new headquarters and research facilities located at 3624 Market Street, 5E Philadelphia, PA 19104. This facility is part of the University City Science Center, and is within short walking distance of the University of Pennsylvania.

In addition to its own office and lab space, PhenoTech will have access to the "Innovation Laboratory", a shared equipment facility offered by the University City Science Center to resident companies and containing some of the major equipment necessary to conduct the Company research program.

"We are delighted to move into this new facility," said Guy Maestre, President and CEO of PhenoTech., "The expanded space will support the Company expansion. PhenoTech will also be able to capitalize on the exciting environment provided by the Science Center and the University of Pennsylvania."

About PhenoTech, Inc.

PhenoTech is a privately held biotechnology company dedicated to the discovery, development and commercialization of highly innovative diagnostic products for use in blood banks. PhenoTech is developing an important new generation of blood typing reagents. These products will improve routine blood transfusions by allowing physicians to match better the blood types of the available blood supplies with that of their patients, resulting in a reduction in potential negative transfusion reactions. The use of our reagents should also significantly reduce the labor costs associated with the blood typing and transfusion process

For more information regarding PhenoTech, Inc. visit www.phenotech.com or e-mail the company at info@phenotech.com.

###

The statements in this document, which are not historical facts, are forward-looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing, commercialization, economic conditions, the impact of competitive or generic products, product liability, the impact of legislative and regulatory compliance and obtaining approvals, and patent, and other risks and uncertainties. Forward-looking statements often contain such words as “estimate”, “anticipate”, “intend”, “plan”, “expect” or “might”, “could” or “should”. Research findings are not always supportable by evidence obtained from **subsequent development trials and the Company can make no assurances that the development trials will yield positive results. Final review decisions made by the FDA and other regulatory agencies concerning development trial results are unpredictable and outside the influence and/or control of the Company.**